Postural orthostatic tachycardia syndrome after COVID-19 vaccination
Authors' conclusion
All patients with postvaccination POTS had pre-existing conditions. There was no evidence of myocardial injuries or echocardiographic abnormalities. The decreased HRV suggests a sympathetic dominant state.
Study context
- Population
- Sequential patients in a postural orthostatic tachycardia syndrome (POTS) clinic reporting new or exacerbated POTS after mRNA COVID-19 vaccination, July 2021–June 20226 women · 4 men
- Participants
- 10 vs 24
- Exposure
- Postvaccination POTS patients vs healthy controls
- Postvaccination POTSn = 10
- Controln = 24reference
- Outcome
- Ambulatory HRV: RMSSD
Methodological detailssingle POTS clinic, sequential patients
- Single POTS clinic
- Sequential patients
Main finding
As reported in the abstract
P = 0.042
Observational data: associations, not effects.
Further findings
SKNA mean amplitude · reduced in POTS
P = 0.011
Standing norepinephrine >600 pg/mL
- Patients with standing norepinephrine levels > 600 pg/mL
- 4
SKNA burst amplitude
- Reduced burst amplitude: 1.67 ± 0.16 μV vs control 4. 3 ± 4.3 μV
- P = 0.018
Clinical course with usual POTS care · 417.2 ± 131.4 days of follow-up
- Relapse with COVID-19 reinfection
- 2
- Relapse with small fiber neuropathy
- 1
- All patients reported improvement
Original publication
Postural orthostatic tachycardia syndrome after COVID-19 vaccination. Heart Rhythm. Published 11 November 2023. doi:10.
Summarised from the published abstract; every number is checked against it